The Swede and Sour of Biosimilars

  • by: |
  • 01/17/2012
The Stockholm Network and Amgen are organising a workshop on Policy Choices and Challenges in the field of biosimilars. The event will take place in Stockholm (Radisson Blu Waterfront Hotel) on 20 February (10.30-15.30).

Today the field of biosimilars presents several important challenges – safety, regulatory, legal and financial – which are the topic of discussion across the globe. Most of these discussions stem from the idea that, unlike the relatively straightforward process of introducing a generic equivalent to an original drug based on a new chemical entity, the process of introducing a biosimilar to an original biological drug is more complex. Indeed, finding the right policy prescription for the creation of a “biosimilar framework” has become a daunting task.

In particular, this workshop will focus on the following aspects:
  1. Managing and determining the element of risk in the creation of biosimilars-related frameworks;
  2. Gaps between policy and practice in the actual use and prescription of biosimilars;
  3. Patient-centric policy vs. cost-containment policy in the field of biosimilars; and
  4. Biosimilars in Sweden – a case study.

Our panel of expert speakers will discuss these burning issues that are now facing every decision-maker dealing with the field of biosimilars. Speakers include:

  • Christofer Fjellner MEP, substitute, European Parliament public health committee;
  • Peter Pitts, president and co-founder, Center for Medicine in the Public Interest.;
  • Dr Nils Wilking, clinical oncologist, Skåne University Hospital;
  • Jörgen Åberg, corporate affairs director, Amgen; and
  • Dr Meir Pugatch, director of research, Stockholm Network.

Lunch and refreshments will be provided.

To RSVP please contact Dr Cristina Palomares, chief operating officer, Stockholm Network on: T +44 20 7354 8888, F: +44 20 7359 8888 or via e-mail on:

Click here now for more information


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog